Darwin Wealth Management’s INmune Bio INMB Stock Holding History

Darwin Wealth Management’s Portfolio INMB Stock Details INMB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-200	Closed	–	–	438
2020 Q1	$0	Buy	+200	New	+$903	﹤0.01%	816

Other funds holding INMB

FAIM

Financial Advocates Investment Management Olympia, Washington $178M AUM 21.03% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

CCM

Covington Capital Management Los Angeles, California $2.32B AUM 12.18% 1-Year Est. Return

FIA

FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return

TPWA

TRUE Private Wealth Advisors Salem, Oregon $1.05B AUM 19.14% 1-Year Est. Return

PAG

Private Advisor Group Morristown, New Jersey $21.3B AUM 22.13% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Darwin Wealth Management's INMB Position: Q2 2020 in Review

Darwin Wealth Management sold out of INmune Bio (INMB) in Q2 2020, closing a stake of 200 shares.

Darwin Wealth Management first reported a position in INMB in Q1 2020 and held it in 1 quarter. The position peaked at $0 in Q1 2020. 16 funds tracked by Wall St. Rank hold INMB as of Q2 2020.

Darwin Wealth Management reported no remaining INmune Bio position as of Q2 2020 after selling out during the quarter.
Darwin Wealth Management sold 200 INmune Bio shares in Q2 2020.
Darwin Wealth Management first reported a position in INmune Bio in Q1 2020 and held it in 1 quarter.
Darwin Wealth Management's INmune Bio position peaked at $0 in Q1 2020.
16 funds tracked by Wall St. Rank held INmune Bio as of Q2 2020.

Based on Darwin Wealth Management's 13F filing for Q2 2020, filed 6 Aug 2020.